View ValuationMYCELX Technologies 将来の成長Future 基準チェック /46MYCELX Technologies利益と収益がそれぞれ年間63.7%と6.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.2% 132.2%なると予測されています。主要情報63.7%収益成長率132.21%EPS成長率Commercial Services 収益成長21.7%収益成長率6.1%将来の株主資本利益率13.20%アナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報お知らせ • Jan 20+ 1 more updateMYCELX Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million. PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering MYCELX Technologies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$200.0k in 2025. New forecast suggests the company will make a loss of US$700.0k in 2026.Breakeven Date Change • Sep 17Forecast to breakeven in 2025The analyst covering MYCELX Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of US$400.0k in 2025. Earnings growth of 79% is required to achieve expected profit on schedule.お知らせ • Apr 08Mycelx Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. For the year the company announced that Given the uncertainty created by the tariff program, which management will continue to monitor, projects have quoted but not signed must be requoted for customer approvals, which could potentially impact project and delivery timelines later in the year. In recognition of the difficult forecast environment, the Company is revising Fiscal Year 2025 revenue to be between $12.5 million and $15.5 million. The wide range reflects the size of the projects in the forecast and project pipeline. The Company will be profitable at the lower end of the range with inclusion of the gain on the Saudi asset sale.お知らせ • Jan 06Mycelx Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the Year 2024. The Company expects its 2024 year-end revenue to be c.a. $4.9 million.お知らせ • Feb 22MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the year 2024. The company is revising its forecasted revenue for 2024, which is now expected to be in the range of $9.0 million to $10.0 million.すべての更新を表示Recent updates分析記事 • May 13Is It Too Late To Consider Buying MYCELX Technologies Corporation (LON:MYX)?MYCELX Technologies Corporation ( LON:MYX ), is not the largest company out there, but it saw a significant share price...Reported Earnings • May 11Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$0.014 (up from US$0.12 loss in FY 2024). Revenue: US$11.7m (up 140% from FY 2024). Net income: US$334.0k (up US$3.06m from FY 2024). Profit margin: 2.8% (up from net loss in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.3%. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.New Risk • Apr 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (UK£10.8m market cap, or US$14.3m).New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (UK£8.16m market cap, or US$11.0m).お知らせ • Jan 20+ 1 more updateMYCELX Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million. PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering MYCELX Technologies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$200.0k in 2025. New forecast suggests the company will make a loss of US$700.0k in 2026.Reported Earnings • Sep 21First half 2025 earnings released: US$0.079 loss per share (vs US$0.059 loss in 1H 2024)First half 2025 results: US$0.079 loss per share (further deteriorated from US$0.059 loss in 1H 2024). Revenue: US$1.67m (down 52% from 1H 2024). Net loss: US$1.92m (loss widened 41% from 1H 2024). Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.New Risk • Sep 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$3.3m Forecast net loss in 1 year: US$145k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.73m market cap, or US$7.81m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Currently unprofitable and not forecast to become profitable next year (US$145k net loss next year). Revenue is less than US$5m (US$3.1m revenue).Breakeven Date Change • Sep 17Forecast to breakeven in 2025The analyst covering MYCELX Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of US$400.0k in 2025. Earnings growth of 79% is required to achieve expected profit on schedule.お知らせ • Jun 10MYCELX Technologies Corporation, Annual General Meeting, Sep 23, 2025MYCELX Technologies Corporation, Annual General Meeting, Sep 23, 2025. Location: the offices of cavendish capital markets limited, one bartholomew close, ec1a 7bl, london United KingdomNew Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.36m market cap, or US$7.11m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (US$4.9m revenue).Reported Earnings • May 13Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.12 loss per share (improved from US$0.16 loss in FY 2023). Revenue: US$4.90m (down 55% from FY 2023). Net loss: US$2.72m (loss narrowed 27% from FY 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.73m market cap, or US$7.49m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$356k net loss in 2 years).お知らせ • Apr 08Mycelx Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. For the year the company announced that Given the uncertainty created by the tariff program, which management will continue to monitor, projects have quoted but not signed must be requoted for customer approvals, which could potentially impact project and delivery timelines later in the year. In recognition of the difficult forecast environment, the Company is revising Fiscal Year 2025 revenue to be between $12.5 million and $15.5 million. The wide range reflects the size of the projects in the forecast and project pipeline. The Company will be profitable at the lower end of the range with inclusion of the gain on the Saudi asset sale.New Risk • Jan 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.92m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Market cap is less than US$10m (UK£7.92m market cap, or US$9.89m).お知らせ • Jan 06Mycelx Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the Year 2024. The Company expects its 2024 year-end revenue to be c.a. $4.9 million.New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (UK£8.91m market cap, or US$11.5m).Reported Earnings • Sep 27First half 2024 earnings released: US$0.059 loss per share (vs US$0.065 loss in 1H 2023)First half 2024 results: US$0.059 loss per share (improved from US$0.065 loss in 1H 2023). Revenue: US$3.50m (down 37% from 1H 2023). Net loss: US$1.36m (loss narrowed 9.6% from 1H 2023). Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat.分析記事 • Sep 24What MYCELX Technologies Corporation's (LON:MYX) P/S Is Not Telling YouIt's not a stretch to say that MYCELX Technologies Corporation's ( LON:MYX ) price-to-sales (or "P/S") ratio of 1.2x...お知らせ • Aug 31MYCELX Technologies Corporation has completed a Follow-on Equity Offering in the amount of £0.711108 million.MYCELX Technologies Corporation has completed a Follow-on Equity Offering in the amount of £0.711108 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 985,957 Price\Range: £0.515 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,292 Price\Range: £0.515 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 48,543 Price\Range: £0.515 Transaction Features: Regulation S; Subsequent Direct ListingNew Risk • Aug 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Market cap is less than US$100m (UK£12.5m market cap, or US$16.5m).お知らせ • Aug 23+ 1 more updateMYCELX Technologies Corporation announced that it expects to receive £0.686108 million in fundingMYCELX Technologies Corporation announced a private placement that it will issue an aggregate of 1,332,248 new common shares of $0.025 each to new and existing investors at an issue price of £0.515 per share for the gross proceeds of £686,108 on August 23, 2024. The Company expects to issue 985,957 New Common Shares pursuant to a placing agreement entered into by the Company with Canaccord Genuity LLC. The Company has also granted a broker option under which up to a further 369,969 new Common Shares may be issued between the date of publication of this Announcement until approximately on August 29, 2024.お知らせ • Jun 06MYCELX Technologies Corporation, Annual General Meeting, Jul 09, 2024MYCELX Technologies Corporation, Annual General Meeting, Jul 09, 2024. Location: the offices of canaccord genuity, 88 wood st, ec2v 7qr, london United KingdomReported Earnings • May 17Full year 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in FY 2022)Full year 2023 results: US$0.16 loss per share (improved from US$0.18 loss in FY 2022). Revenue: US$10.9m (up 8.8% from FY 2022). Net loss: US$3.71m (loss narrowed 7.1% from FY 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Apr 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (UK£11.6m market cap, or US$14.7m).分析記事 • Feb 24What MYCELX Technologies Corporation's (LON:MYX) P/S Is Not Telling YouIt's not a stretch to say that MYCELX Technologies Corporation's ( LON:MYX ) price-to-sales (or "P/S") ratio of 1.2x...お知らせ • Feb 22MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the year 2024. The company is revising its forecasted revenue for 2024, which is now expected to be in the range of $9.0 million to $10.0 million.Reported Earnings • Sep 21First half 2023 earnings released: US$0.065 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.065 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$5.57m (up 51% from 1H 2022). Net loss: US$1.51m (loss narrowed 48% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 20MYCELX Technologies Corporation's (LON:MYX) CEO Looks Like They Deserve Their Pay PacketKey Insights MYCELX Technologies' Annual General Meeting to take place on 26th of September Total pay for CEO Connie...お知らせ • Jun 21MYCELX Technologies Corporation, Annual General Meeting, Sep 26, 2023MYCELX Technologies Corporation, Annual General Meeting, Sep 26, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Canaccord Genuity, 88 Wood St, London EC2V 7QR London United KingdomReported Earnings • May 18Full year 2022 earnings released: US$0.18 loss per share (vs US$0.073 loss in FY 2021)Full year 2022 results: US$0.18 loss per share (further deteriorated from US$0.073 loss in FY 2021). Revenue: US$10.0m (up 18% from FY 2021). Net loss: US$3.99m (loss widened 180% from FY 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jan 31MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2022MYCELX Technologies Corporation provided earnings guidance for the year 2022. The Company exceeded previous guidance by achieving 2022 revenue of ca.$10.0 million, EBITDA of ca. negative $2.5 million and a net loss of ca.$4.0 million due to an increase in activity in the final month of the year which included an emergency response deployment in Saudi Arabia, higher than expected year end media sales and an increased scope for a REGEN project that was completed in December.Price Target Changed • Nov 16Price target decreased to UK£0.95Down from UK£2.95, the current price target is provided by 1 analyst. New target price is 228% above last closing price of UK£0.29. Stock is down 63% over the past year. The company posted a net loss per share of US$0.073 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Tom Lamb was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 27First half 2022 earnings released: US$0.13 loss per share (vs US$0.022 profit in 1H 2021)First half 2022 results: US$0.13 loss per share (down from US$0.022 profit in 1H 2021). Revenue: US$3.70m (down 11% from 1H 2021). Net loss: US$2.88m (down US$3.32m from profit in 1H 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 15MYCELX Technologies Corporation Revises Revenue Guidance for the Fiscal Year 2022MYCELX Technologies Corporation revised revenue guidance for the fiscal year 2022. For the period, company is revising its guidance and now expects 10% year-on-year revenue growth.Board Change • Aug 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Tom Lamb was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jun 13MYCELX Technologies Corporation, Annual General Meeting, Jul 13, 2022MYCELX Technologies Corporation, Annual General Meeting, Jul 13, 2022, at 13:00 Coordinated Universal Time. Location: Canaccord Genuity, 88 Wood St, London EC2V 7QR London, United KingdomReported Earnings • May 18Full year 2021 earnings released: US$0.073 loss per share (vs US$0.31 loss in FY 2020)Full year 2021 results: US$0.073 loss per share (up from US$0.31 loss in FY 2020). Revenue: US$8.48m (up 19% from FY 2020). Net loss: US$1.43m (loss narrowed 77% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings.お知らせ • Feb 11MYCELX Technologies Corporation Provides Unaudited Earnings Guidance for the Year Ended December 31, 2021 and 2022MYCELX Technologies Corporation provided unaudited earnings guidance for the year ended December 31, 2021. Anticipated unaudited 2021 revenue of $8.5 million (2020: $7.1 million).In 2022 the Company is targeting a similar level of year-on-year revenue growth but this remains subject to the timing of anticipated contract wins and renewals.お知らせ • Jan 26MYCELX Technologies Corporation Announces Successful Trial of PFAS Remediation SystemMYCELX Technologies Corporation announced that it has successfully completed a trial in the United States of its PFAS remediation system which deploys its patented MYCELX technology. The results of the trial confirm the ability of MYCELX's PFAS remediation system to reduce contamination to non-detect level in a single pass through the system. As part of its continuing strategy to address the PFAS remediation market, MYCELX commenced an important trial at an industrial site in Newburgh, New York, in December 2021. The trial involved treating PFAS contaminated water from a storm water retention pond. The likely source of the PFAS contamination was aqueous film forming foams (AFFF). The presence of additional contaminants, such as glycols from plane de-icing procedures, ensured a challenging and complex water source to remediate. MYCELX installed a mobile trial system using the patented MYCELX technology for PFAS remediation. Earlier generations of this technology have already been successfully deployed in Australia, which is recognised as being at the forefront of PFAS remediation. The MYCELX solution is designed to offer a lower life-cycle cost of treatment, primarily due to significantly reduced waste versus alternative technologies. The trial successfully demonstrated the ability of the MYCELX system to completely remove all detected chemicals to non-detectable concentrations in a single pass, achieving a 99.99% removal efficiency. Complete removal of this spectrum of PFAS chemicals eliminates both regulated PFAS compounds, and complete removal will prevent future degradation of components into PFAS compounds that may be subject to future regulation. The technology provided a failsafe treatment with no rise in differential pressures or increase in outlet concentrations over the length of the trial.Reported Earnings • Oct 01First half 2021 earnings released: EPS US$0.022 (vs US$0.14 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$4.16m (up 14% from 1H 2020). Net income: US$435.0k (up US$3.21m from 1H 2020). Profit margin: 10% (up from net loss in 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.Executive Departure • Jul 13Independent Non-Executive Chairman Timothy John Eggar has left the companyOn the 7th of July, Timothy John Eggar's tenure as Independent Non-Executive Chairman ended after 9.9 years in the role. We don't have any record of a personal shareholding under Timothy John's name. Timothy John is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.29 years.分析記事 • Jul 01We Discuss Why MYCELX Technologies Corporation's (LON:MYX) CEO Compensation May Be Closely ReviewedThe results at MYCELX Technologies Corporation ( LON:MYX ) have been quite disappointing recently and CEO Connie Mixon...分析記事 • May 31Is MYCELX Technologies (LON:MYX) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Reported Earnings • May 28Full year 2020 earnings released: US$0.31 loss per share (vs US$0.15 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$7.10m (down 40% from FY 2019). Net loss: US$6.09m (loss widened 106% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.お知らせ • May 15MYCELX Technologies Corporation Announces the Validation and Capacity Upgrade of its PFAS system at an Australian Department of Defence locationMYCELX Technologies Corporation announced the validation and capacity upgrade of its PFAS system at an Australian Department of Defence location. This follows a deployment of the PFAS system by the Australian partner in 2018. The capacity upgrade contract was awarded as a consequence of the robust operating performance demonstrated over a two-year period, within budget, as well as allowing the customer to both support, improve and adhere to, its environmental goals. PFAS (Perfluoroalkyl substances) remediation has been a key area of organic diversification for MYCELX and the Company is delighted with the progress made. This re-deployment is a step forward for the Company and has the potential to lead to further contract awards in due course. With the increasing awareness and legislation worldwide, the benefits of MYCELX's proprietary technology allows for efficient removal of toxic "forever" chemicals associated with adhesives and Teflon related products and has the potential to be a leading solution for PFAS remediation worldwide.Is New 90 Day High Low • Feb 04New 90-day low: UK£0.23The company is down 21% from its price of UK£0.29 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 7.0% over the same period.Is New 90 Day High Low • Jan 19New 90-day low: UK£0.28The company is down 2.0% from its price of UK£0.29 on 21 October 2020. The British market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 30New 90-day high: UK£0.33The company is up 12% from its price of UK£0.29 on 01 October 2020. The British market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Commercial Services industry, which is up 9.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: UK£0.33The company is down 30% from its price of UK£0.47 on 26 June 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is down 2.0% over the same period.Reported Earnings • Sep 23First half earnings releasedOver the last 12 months the company has reported total losses of US$5.83m, with earnings decreasing by US$7.42m from the prior year. Total revenue was US$6.48m over the last 12 months, down 73% from the prior year.業績と収益の成長予測AIM:MYX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202713112112/31/202611022112/31/2025120-1-1N/A9/30/20257-1-2-2N/A6/30/20253-3-2-2N/A3/31/20254-3-2-2N/A12/31/20245-3-2-2N/A9/30/20247-3-2-2N/A6/30/20249-4-2-2N/A3/31/202410-4-1-1N/A12/31/202311-4-1-1N/A9/30/202311-3-1-1N/A6/30/202312-3-1-1N/A3/31/202311-3-2-2N/A12/31/202210-4-4-3N/A9/30/20229-4-4-3N/A6/30/20228-5-5-4N/A3/31/20228-3-4-4N/A12/31/20218-1-4-3N/A9/30/20218-2-4-3N/A6/30/20218-3-3-3N/A3/31/20217-4-3-2N/A12/31/20207-6-2-1N/A9/30/20207-6-10N/A6/30/20206-601N/A3/31/20209-4-10N/A12/31/201912-3-3-2N/A9/30/201918-1N/A-2N/A6/30/2019242N/A-2N/A3/31/2019252N/A-1N/A12/31/2018273N/A0N/A9/30/2018232N/A1N/A6/30/2018201N/A1N/A3/31/2018170N/A1N/A12/31/201714-1N/A0N/A9/30/201712-2N/A0N/A6/30/201710-2N/A-1N/A3/31/20179-3N/A0N/A12/31/20168-3N/A0N/A9/30/20168-3N/A0N/A6/30/20169-4N/A0N/A3/31/201611-4N/A-1N/A12/31/201514-4N/A-2N/A9/30/201514-4N/A-2N/A6/30/201515-5N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MYXの予測収益成長率 (年間63.7% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: MYXの収益 ( 63.7% ) はUK市場 ( 11.4% ) よりも速いペースで成長すると予測されています。高成長収益: MYXの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: MYXの収益 ( 6.1% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: MYXの収益 ( 6.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MYXの 自己資本利益率 は、3年後には低くなると予測されています ( 13.2 %)。成長企業の発掘7D1Y7D1Y7D1YCommercial-services 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 10:37終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MYCELX Technologies Corporation 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Alexander BrooksCanaccord GenuityAndrew Murray DarleyCavendishJohn-Marc BunceCavendish2 その他のアナリストを表示
お知らせ • Jan 20+ 1 more updateMYCELX Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million. PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.
Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering MYCELX Technologies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$200.0k in 2025. New forecast suggests the company will make a loss of US$700.0k in 2026.
Breakeven Date Change • Sep 17Forecast to breakeven in 2025The analyst covering MYCELX Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of US$400.0k in 2025. Earnings growth of 79% is required to achieve expected profit on schedule.
お知らせ • Apr 08Mycelx Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. For the year the company announced that Given the uncertainty created by the tariff program, which management will continue to monitor, projects have quoted but not signed must be requoted for customer approvals, which could potentially impact project and delivery timelines later in the year. In recognition of the difficult forecast environment, the Company is revising Fiscal Year 2025 revenue to be between $12.5 million and $15.5 million. The wide range reflects the size of the projects in the forecast and project pipeline. The Company will be profitable at the lower end of the range with inclusion of the gain on the Saudi asset sale.
お知らせ • Jan 06Mycelx Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the Year 2024. The Company expects its 2024 year-end revenue to be c.a. $4.9 million.
お知らせ • Feb 22MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the year 2024. The company is revising its forecasted revenue for 2024, which is now expected to be in the range of $9.0 million to $10.0 million.
分析記事 • May 13Is It Too Late To Consider Buying MYCELX Technologies Corporation (LON:MYX)?MYCELX Technologies Corporation ( LON:MYX ), is not the largest company out there, but it saw a significant share price...
Reported Earnings • May 11Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$0.014 (up from US$0.12 loss in FY 2024). Revenue: US$11.7m (up 140% from FY 2024). Net income: US$334.0k (up US$3.06m from FY 2024). Profit margin: 2.8% (up from net loss in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.3%. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
New Risk • Apr 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (UK£10.8m market cap, or US$14.3m).
New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (UK£8.16m market cap, or US$11.0m).
お知らせ • Jan 20+ 1 more updateMYCELX Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million. PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.
Breakeven Date Change • Dec 31No longer forecast to breakevenThe analyst covering MYCELX Technologies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$200.0k in 2025. New forecast suggests the company will make a loss of US$700.0k in 2026.
Reported Earnings • Sep 21First half 2025 earnings released: US$0.079 loss per share (vs US$0.059 loss in 1H 2024)First half 2025 results: US$0.079 loss per share (further deteriorated from US$0.059 loss in 1H 2024). Revenue: US$1.67m (down 52% from 1H 2024). Net loss: US$1.92m (loss widened 41% from 1H 2024). Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
New Risk • Sep 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$3.3m Forecast net loss in 1 year: US$145k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.73m market cap, or US$7.81m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Currently unprofitable and not forecast to become profitable next year (US$145k net loss next year). Revenue is less than US$5m (US$3.1m revenue).
Breakeven Date Change • Sep 17Forecast to breakeven in 2025The analyst covering MYCELX Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of US$400.0k in 2025. Earnings growth of 79% is required to achieve expected profit on schedule.
お知らせ • Jun 10MYCELX Technologies Corporation, Annual General Meeting, Sep 23, 2025MYCELX Technologies Corporation, Annual General Meeting, Sep 23, 2025. Location: the offices of cavendish capital markets limited, one bartholomew close, ec1a 7bl, london United Kingdom
New Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.36m market cap, or US$7.11m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$2.2m). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (US$4.9m revenue).
Reported Earnings • May 13Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.12 loss per share (improved from US$0.16 loss in FY 2023). Revenue: US$4.90m (down 55% from FY 2023). Net loss: US$2.72m (loss narrowed 27% from FY 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£5.73m market cap, or US$7.49m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$356k net loss in 2 years).
お知らせ • Apr 08Mycelx Technologies Corporation Updates Earnings Guidance for 2025MYCELX Technologies Corporation updated earnings guidance for 2025. For the year the company announced that Given the uncertainty created by the tariff program, which management will continue to monitor, projects have quoted but not signed must be requoted for customer approvals, which could potentially impact project and delivery timelines later in the year. In recognition of the difficult forecast environment, the Company is revising Fiscal Year 2025 revenue to be between $12.5 million and $15.5 million. The wide range reflects the size of the projects in the forecast and project pipeline. The Company will be profitable at the lower end of the range with inclusion of the gain on the Saudi asset sale.
New Risk • Jan 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.92m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.7% per year over the past 5 years. Market cap is less than US$10m (UK£7.92m market cap, or US$9.89m).
お知らせ • Jan 06Mycelx Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the Year 2024. The Company expects its 2024 year-end revenue to be c.a. $4.9 million.
New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (UK£8.91m market cap, or US$11.5m).
Reported Earnings • Sep 27First half 2024 earnings released: US$0.059 loss per share (vs US$0.065 loss in 1H 2023)First half 2024 results: US$0.059 loss per share (improved from US$0.065 loss in 1H 2023). Revenue: US$3.50m (down 37% from 1H 2023). Net loss: US$1.36m (loss narrowed 9.6% from 1H 2023). Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat.
分析記事 • Sep 24What MYCELX Technologies Corporation's (LON:MYX) P/S Is Not Telling YouIt's not a stretch to say that MYCELX Technologies Corporation's ( LON:MYX ) price-to-sales (or "P/S") ratio of 1.2x...
お知らせ • Aug 31MYCELX Technologies Corporation has completed a Follow-on Equity Offering in the amount of £0.711108 million.MYCELX Technologies Corporation has completed a Follow-on Equity Offering in the amount of £0.711108 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 985,957 Price\Range: £0.515 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 346,292 Price\Range: £0.515 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 48,543 Price\Range: £0.515 Transaction Features: Regulation S; Subsequent Direct Listing
New Risk • Aug 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Market cap is less than US$100m (UK£12.5m market cap, or US$16.5m).
お知らせ • Aug 23+ 1 more updateMYCELX Technologies Corporation announced that it expects to receive £0.686108 million in fundingMYCELX Technologies Corporation announced a private placement that it will issue an aggregate of 1,332,248 new common shares of $0.025 each to new and existing investors at an issue price of £0.515 per share for the gross proceeds of £686,108 on August 23, 2024. The Company expects to issue 985,957 New Common Shares pursuant to a placing agreement entered into by the Company with Canaccord Genuity LLC. The Company has also granted a broker option under which up to a further 369,969 new Common Shares may be issued between the date of publication of this Announcement until approximately on August 29, 2024.
お知らせ • Jun 06MYCELX Technologies Corporation, Annual General Meeting, Jul 09, 2024MYCELX Technologies Corporation, Annual General Meeting, Jul 09, 2024. Location: the offices of canaccord genuity, 88 wood st, ec2v 7qr, london United Kingdom
Reported Earnings • May 17Full year 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in FY 2022)Full year 2023 results: US$0.16 loss per share (improved from US$0.18 loss in FY 2022). Revenue: US$10.9m (up 8.8% from FY 2022). Net loss: US$3.71m (loss narrowed 7.1% from FY 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Apr 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (UK£11.6m market cap, or US$14.7m).
分析記事 • Feb 24What MYCELX Technologies Corporation's (LON:MYX) P/S Is Not Telling YouIt's not a stretch to say that MYCELX Technologies Corporation's ( LON:MYX ) price-to-sales (or "P/S") ratio of 1.2x...
お知らせ • Feb 22MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2024MYCELX Technologies Corporation provided earnings guidance for the year 2024. The company is revising its forecasted revenue for 2024, which is now expected to be in the range of $9.0 million to $10.0 million.
Reported Earnings • Sep 21First half 2023 earnings released: US$0.065 loss per share (vs US$0.13 loss in 1H 2022)First half 2023 results: US$0.065 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$5.57m (up 51% from 1H 2022). Net loss: US$1.51m (loss narrowed 48% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 20MYCELX Technologies Corporation's (LON:MYX) CEO Looks Like They Deserve Their Pay PacketKey Insights MYCELX Technologies' Annual General Meeting to take place on 26th of September Total pay for CEO Connie...
お知らせ • Jun 21MYCELX Technologies Corporation, Annual General Meeting, Sep 26, 2023MYCELX Technologies Corporation, Annual General Meeting, Sep 26, 2023, at 13:00 Coordinated Universal Time. Location: the offices of Canaccord Genuity, 88 Wood St, London EC2V 7QR London United Kingdom
Reported Earnings • May 18Full year 2022 earnings released: US$0.18 loss per share (vs US$0.073 loss in FY 2021)Full year 2022 results: US$0.18 loss per share (further deteriorated from US$0.073 loss in FY 2021). Revenue: US$10.0m (up 18% from FY 2021). Net loss: US$3.99m (loss widened 180% from FY 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jan 31MYCELX Technologies Corporation Provides Earnings Guidance for the Year 2022MYCELX Technologies Corporation provided earnings guidance for the year 2022. The Company exceeded previous guidance by achieving 2022 revenue of ca.$10.0 million, EBITDA of ca. negative $2.5 million and a net loss of ca.$4.0 million due to an increase in activity in the final month of the year which included an emergency response deployment in Saudi Arabia, higher than expected year end media sales and an increased scope for a REGEN project that was completed in December.
Price Target Changed • Nov 16Price target decreased to UK£0.95Down from UK£2.95, the current price target is provided by 1 analyst. New target price is 228% above last closing price of UK£0.29. Stock is down 63% over the past year. The company posted a net loss per share of US$0.073 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Tom Lamb was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 27First half 2022 earnings released: US$0.13 loss per share (vs US$0.022 profit in 1H 2021)First half 2022 results: US$0.13 loss per share (down from US$0.022 profit in 1H 2021). Revenue: US$3.70m (down 11% from 1H 2021). Net loss: US$2.88m (down US$3.32m from profit in 1H 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Commercial Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 15MYCELX Technologies Corporation Revises Revenue Guidance for the Fiscal Year 2022MYCELX Technologies Corporation revised revenue guidance for the fiscal year 2022. For the period, company is revising its guidance and now expects 10% year-on-year revenue growth.
Board Change • Aug 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Chairman Tom Lamb was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jun 13MYCELX Technologies Corporation, Annual General Meeting, Jul 13, 2022MYCELX Technologies Corporation, Annual General Meeting, Jul 13, 2022, at 13:00 Coordinated Universal Time. Location: Canaccord Genuity, 88 Wood St, London EC2V 7QR London, United Kingdom
Reported Earnings • May 18Full year 2021 earnings released: US$0.073 loss per share (vs US$0.31 loss in FY 2020)Full year 2021 results: US$0.073 loss per share (up from US$0.31 loss in FY 2020). Revenue: US$8.48m (up 19% from FY 2020). Net loss: US$1.43m (loss narrowed 77% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 11MYCELX Technologies Corporation Provides Unaudited Earnings Guidance for the Year Ended December 31, 2021 and 2022MYCELX Technologies Corporation provided unaudited earnings guidance for the year ended December 31, 2021. Anticipated unaudited 2021 revenue of $8.5 million (2020: $7.1 million).In 2022 the Company is targeting a similar level of year-on-year revenue growth but this remains subject to the timing of anticipated contract wins and renewals.
お知らせ • Jan 26MYCELX Technologies Corporation Announces Successful Trial of PFAS Remediation SystemMYCELX Technologies Corporation announced that it has successfully completed a trial in the United States of its PFAS remediation system which deploys its patented MYCELX technology. The results of the trial confirm the ability of MYCELX's PFAS remediation system to reduce contamination to non-detect level in a single pass through the system. As part of its continuing strategy to address the PFAS remediation market, MYCELX commenced an important trial at an industrial site in Newburgh, New York, in December 2021. The trial involved treating PFAS contaminated water from a storm water retention pond. The likely source of the PFAS contamination was aqueous film forming foams (AFFF). The presence of additional contaminants, such as glycols from plane de-icing procedures, ensured a challenging and complex water source to remediate. MYCELX installed a mobile trial system using the patented MYCELX technology for PFAS remediation. Earlier generations of this technology have already been successfully deployed in Australia, which is recognised as being at the forefront of PFAS remediation. The MYCELX solution is designed to offer a lower life-cycle cost of treatment, primarily due to significantly reduced waste versus alternative technologies. The trial successfully demonstrated the ability of the MYCELX system to completely remove all detected chemicals to non-detectable concentrations in a single pass, achieving a 99.99% removal efficiency. Complete removal of this spectrum of PFAS chemicals eliminates both regulated PFAS compounds, and complete removal will prevent future degradation of components into PFAS compounds that may be subject to future regulation. The technology provided a failsafe treatment with no rise in differential pressures or increase in outlet concentrations over the length of the trial.
Reported Earnings • Oct 01First half 2021 earnings released: EPS US$0.022 (vs US$0.14 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$4.16m (up 14% from 1H 2020). Net income: US$435.0k (up US$3.21m from 1H 2020). Profit margin: 10% (up from net loss in 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
Executive Departure • Jul 13Independent Non-Executive Chairman Timothy John Eggar has left the companyOn the 7th of July, Timothy John Eggar's tenure as Independent Non-Executive Chairman ended after 9.9 years in the role. We don't have any record of a personal shareholding under Timothy John's name. Timothy John is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.29 years.
分析記事 • Jul 01We Discuss Why MYCELX Technologies Corporation's (LON:MYX) CEO Compensation May Be Closely ReviewedThe results at MYCELX Technologies Corporation ( LON:MYX ) have been quite disappointing recently and CEO Connie Mixon...
分析記事 • May 31Is MYCELX Technologies (LON:MYX) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Reported Earnings • May 28Full year 2020 earnings released: US$0.31 loss per share (vs US$0.15 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$7.10m (down 40% from FY 2019). Net loss: US$6.09m (loss widened 106% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
お知らせ • May 15MYCELX Technologies Corporation Announces the Validation and Capacity Upgrade of its PFAS system at an Australian Department of Defence locationMYCELX Technologies Corporation announced the validation and capacity upgrade of its PFAS system at an Australian Department of Defence location. This follows a deployment of the PFAS system by the Australian partner in 2018. The capacity upgrade contract was awarded as a consequence of the robust operating performance demonstrated over a two-year period, within budget, as well as allowing the customer to both support, improve and adhere to, its environmental goals. PFAS (Perfluoroalkyl substances) remediation has been a key area of organic diversification for MYCELX and the Company is delighted with the progress made. This re-deployment is a step forward for the Company and has the potential to lead to further contract awards in due course. With the increasing awareness and legislation worldwide, the benefits of MYCELX's proprietary technology allows for efficient removal of toxic "forever" chemicals associated with adhesives and Teflon related products and has the potential to be a leading solution for PFAS remediation worldwide.
Is New 90 Day High Low • Feb 04New 90-day low: UK£0.23The company is down 21% from its price of UK£0.29 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Jan 19New 90-day low: UK£0.28The company is down 2.0% from its price of UK£0.29 on 21 October 2020. The British market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 30New 90-day high: UK£0.33The company is up 12% from its price of UK£0.29 on 01 October 2020. The British market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Commercial Services industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: UK£0.33The company is down 30% from its price of UK£0.47 on 26 June 2020. The British market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is down 2.0% over the same period.
Reported Earnings • Sep 23First half earnings releasedOver the last 12 months the company has reported total losses of US$5.83m, with earnings decreasing by US$7.42m from the prior year. Total revenue was US$6.48m over the last 12 months, down 73% from the prior year.